JOP20190281A1 - مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه - Google Patents

مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه

Info

Publication number
JOP20190281A1
JOP20190281A1 JOP/2019/0281A JOP20190281A JOP20190281A1 JO P20190281 A1 JOP20190281 A1 JO P20190281A1 JO P20190281 A JOP20190281 A JO P20190281A JO P20190281 A1 JOP20190281 A1 JO P20190281A1
Authority
JO
Jordan
Prior art keywords
cancer
treatment
same
diphenylpyrimidin
prevention
Prior art date
Application number
JOP/2019/0281A
Other languages
English (en)
Inventor
Chae Won Park
Kwangho Lee
Myoung Eun Jung
Hyeon Jeong Choe
Hwan Kim
Krishna Babu Duggirala
Chong Hak Chae
Byeong Uk Jeon
Byoung Chul Cho
Gildon Choi
Inji Shin
Original Assignee
Korea Res Inst Chemical Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Chemical Tech filed Critical Korea Res Inst Chemical Tech
Publication of JOP20190281A1 publication Critical patent/JOP20190281A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention

Abstract

يتعلق الاختراع الحالي بمشتق<span dir="LTR"> N2</span>، <span dir="LTR">N4-</span>ثنائي فينيل بيريميدين - 2، ?- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه. يُظهر المُشتق تأثير مُثبط لنشاط<span dir="LTR"> EGFR </span>ضعيف نسبيًا على النوع البري من<span dir="LTR"> EGFR</span>، قدرة تثبيط مرتفعة على طفرة<span dir="LTR"> EGFR</span>، وقدرة تثبيط مرتفعة على<span dir="LTR"> FLT3 </span>وطفرة<span dir="LTR"> FLT3 </span>أيضًا، ومن ثم يُمكن استخدامها بشكل فعال لعلاج السرطان نتيجة طفرة<span dir="LTR"> EGFR </span>أو سرطان بـ<span dir="LTR"> FLT3 </span>أو طفرة منه، ويُظهر المشتق تأثير تآزري عند زمن إعطاء التوليفة، ومن ثم يُمكن استخدامه بشكل فعال للعلاج الخاص بإعطاء توليفة<span dir="LTR">.</span>
JOP/2019/0281A 2017-06-13 2017-06-16 مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه JOP20190281A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170073907 2017-06-13
KR1020170146241A KR20180135781A (ko) 2017-06-13 2017-11-03 N2,n4-디페닐피리미딘-2,4-디아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
JOP20190281A1 true JOP20190281A1 (ar) 2019-12-02

Family

ID=70972831

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0281A JOP20190281A1 (ar) 2017-06-13 2017-06-16 مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه

Country Status (17)

Country Link
US (2) US11253516B2 (ar)
EP (1) EP3640246B1 (ar)
JP (1) JP6945015B2 (ar)
KR (2) KR20180135781A (ar)
CN (1) CN110740999A (ar)
AU (1) AU2018286361B2 (ar)
BR (1) BR112019026253A2 (ar)
CA (1) CA3066083C (ar)
CL (1) CL2019003589A1 (ar)
EA (1) EA201992722A1 (ar)
IL (1) IL271291B2 (ar)
JO (1) JOP20190281A1 (ar)
MX (1) MX2019014548A (ar)
NZ (1) NZ760089A (ar)
SA (1) SA519410722B1 (ar)
WO (1) WO2018230934A1 (ar)
ZA (1) ZA201908241B (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101992621B1 (ko) 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US20220267294A1 (en) * 2019-06-20 2022-08-25 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of src tyrosine kinase
JP7330546B6 (ja) * 2019-06-20 2024-02-21 オンコビクス・カンパニー・リミテッド 癌細胞の成長を抑制するピリミジン誘導体およびその医薬用途
WO2021003417A1 (en) * 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
EP4079730A4 (en) * 2019-12-16 2023-11-29 Oncobix Co., Ltd. NOVEL DEUTERIUM SUBSTITUTED PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
CN113896744B (zh) * 2020-07-06 2024-04-16 成都先导药物开发股份有限公司 一种选择性egfr抑制剂
CN112390760B (zh) * 2020-10-15 2022-07-29 北京师范大学 靶向fak的化合物及其制备方法和应用
CN112239422B (zh) * 2020-10-16 2022-07-22 河北化工医药职业技术学院 一种布格替尼中间体、其盐、其制备方法以及布格替尼的制备方法
EP4274567A1 (en) * 2021-01-05 2023-11-15 Sumitomo Pharma Oncology, Inc. Forms and formulations of a tyrosine kinase non-receptor 1 (tnk1) inhibitor
US20240051940A1 (en) * 2021-02-08 2024-02-15 Accutar Biotechnology Inc. Sulfonamides with egfr inhibition activities and their use thereof
AU2022250976A1 (en) * 2021-04-01 2023-08-17 Industry-Academic Cooperation Foundation, Yonsei University Pyrimidine derivative having protein kinase inhibitory activity, and therapeutic pharmaceutical composition comprising same
IL310020A (en) * 2021-07-13 2024-03-01 Korea Res Inst Chemical Tech Innovative 2,4-pyrimidine-diamine derivatives, their preparation method and pharmaceutical preparations containing them as an active substance for the prevention and treatment of cancer
WO2023201024A1 (en) * 2022-04-15 2023-10-19 Bridge Biotherapeutics, Inc. Composition and treatment for cancer with mutations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001759A (es) * 2003-08-15 2006-05-12 Novartis Ag 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios.
RS53588B1 (en) 2006-12-08 2015-02-27 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
EA029131B1 (ru) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
ES2698298T3 (es) * 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
KR101656382B1 (ko) 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
US10058559B2 (en) * 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
US10053458B2 (en) 2014-06-17 2018-08-21 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
EP3195866B1 (en) 2014-08-22 2020-11-18 FUJIFILM Corporation Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof
KR101789934B1 (ko) 2015-07-31 2017-10-26 중앙대학교 산학협력단 상피세포성장인자수용체 변이체를 가진 종양 진단 및 종양 성장 억제 활성을 갖는 신규 화합물 및 이를 포함하는 의학적 용도

Also Published As

Publication number Publication date
EP3640246A1 (en) 2020-04-22
NZ760089A (en) 2022-10-28
IL271291B2 (en) 2023-02-01
MX2019014548A (es) 2020-02-07
CA3066083A1 (en) 2018-12-20
EA201992722A1 (ru) 2020-04-02
EP3640246A4 (en) 2020-08-05
EP3640246C0 (en) 2023-11-01
CN110740999A (zh) 2020-01-31
JP2020523360A (ja) 2020-08-06
SA519410722B1 (ar) 2023-03-15
IL271291A (en) 2020-01-30
ZA201908241B (en) 2021-04-28
AU2018286361B2 (en) 2020-11-19
EP3640246B1 (en) 2023-11-01
CL2019003589A1 (es) 2020-07-03
US11253516B2 (en) 2022-02-22
US20200179384A1 (en) 2020-06-11
WO2018230934A1 (ko) 2018-12-20
CA3066083C (en) 2021-11-30
US20220249482A1 (en) 2022-08-11
BR112019026253A2 (pt) 2020-06-23
KR20180135815A (ko) 2018-12-21
JP6945015B2 (ja) 2021-10-06
KR20180135781A (ko) 2018-12-21
KR102023156B1 (ko) 2019-09-19
IL271291B (en) 2022-10-01
AU2018286361A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
JOP20190281A1 (ar) مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
NZ733174A (en) Quinazoline derivatives used to treat hiv
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
JOP20180025B1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12020550491A1 (en) Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer
TW201613919A (en) Inhibitors of Bruton&#39;s tyrosine kinase
WO2015194764A3 (ko) 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3336100A4 (en) PEPTIDE WITH EFFECT FOR PREVENTING OR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM THEREFOR AS AN ACTIVE SUBSTANCE
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
MX2017014471A (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
MX2015014707A (es) Proceso de obtencion y composicion farmaceutica de esomeprazol inyectable para el tratamiento de trastornos gastricos.